Detecting unstable periodic spatio-temporal states of spatial extended chaotic systems

The method of detection of the unstable periodic spatio-temporal states of spatial extended chaotic systems has been proposed. The application of this method is illustrated by the consideration of two different systems: i) the fluid model of Pierce diode being one of the fundamental system of the physics of plasmas and microwave electronics and ii) the complex one-dimensional Ginzburg-Landau equation demonstrating different regimes of spatio-temporal chaos.Comment: 6 pages, 7 figure

Controlling chaos in spatially extended beam-plasma system by the continuous delayed feedback

In present paper we discuss the control of complex spatio-temporal dynamics in a {spatially extended} non-linear system (fluid model of Pierce diode) based on the concepts of controlling chaos in the systems with few degrees of freedom. A presented method is connected with stabilization of unstable homogeneous equilibrium state and the unstable spatio-temporal periodical states analogous to unstable periodic orbits of chaotic dynamics of the systems with few degrees of freedom. We show that this method is effective and allows to achieve desired regular dynamics chosen from a number of possible in the considered system.Comment: 12 pages, 12 figure

Investigation of the complex dynamics and regime control in Pierce diode with the delay feedback

In this paper the dynamics of Pierce diode with overcritical current under the influence of delay feedback is investigated. The system without feedback demonstrates complex behaviour including chaotic regimes. The possibility of oscillation regime control depending on the delay feedback parameter values is shown. Also the paper describes construction of a finite-dimensional model of electron beam behaviour, which is based on the Galerkin approximation by linear modes expansion. The dynamics of the model is close to the one given by the distributed model.Comment: 18 pages, 6 figures, published in Int. J. Electronics. 91, 1 (2004) 1-1

Выделение двумерного электрического поля в уравнениях возбуждения для полых волноводов

The traditional excitation equations of the Vainshtein waveguide excitation theory based on presenting the field excited by extraneous sources as a sum of TE and TM eigenwaves of the hollow waveguide, which transversal components form the complete basis in the class of the transversal vectors of a waveguide section. However, in the excitation sources area (longitudinal sonde, electron beam) the waveguide is not hollow and the potential transverse electric field appears in this area. The transversal electric field completes the basis of TE and TM waves. This is not taken into account in the traditional excitation equations. In this paper, the necessary correction of the excitation equations in the sources area is obtained

Clarifying the role of three-dimensional transvaginal sonography in reproductive medicine: an evidenced-based appraisal

This overview describes and illustrates the clinical applications of three-dimensional transvaginal sonography in reproductive medicine. Its main applications include assessment of uterine anomalies, intrauterine pathology, tubal patency, polycystic ovaries, ovarian follicular monitoring and endometrial receptivity. It is also useful for detailed evaluation of failed and/or ectopic pregnancy. Three-dimensional color Doppler sonography provides enhanced depiction of uterine, endometrial, and ovarian vascularity

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Background Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS. Methods In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had been diagnosed with locally excised, hormone-receptor-positive DCIS. Eligible women were randomly assigned in a 1:1 ratio by central computer allocation to receive 1 mg oral anastrozole or 20 mg oral tamoxifen every day for 5 years. Randomisation was stratified by major centre or hub and was done in blocks (six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation and only the trial statistician had access to treatment allocation. The primary endpoint was all recurrence, including recurrent DCIS and new contralateral tumours. All analyses were done on a modified intention-to-treat basis (in all women who were randomised and did not revoke consent for their data to be included) and proportional hazard models were used to compute hazard ratios and corresponding confidence intervals. This trial is registered at the ISRCTN registry, number ISRCTN37546358. Results Between March 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries and randomly assigned them to receive anastrozole (1449 analysed) or tamoxifen (1489 analysed). Median follow-up was 7·2 years (IQR 5·6–8·9), and 144 breast cancer recurrences were recorded. We noted no statistically significant difference in overall recurrence (67 recurrences for anastrozole vs 77 for tamoxifen; HR 0·89 [95% CI 0·64–1·23]). The non-inferiority of anastrozole was established (upper 95% CI <1·25), but its superiority to tamoxifen was not (p=0·49). A total of 69 deaths were recorded (33 for anastrozole vs 36 for tamoxifen; HR 0·93 [95% CI 0·58–1·50], p=0·78), and no specific cause was more common in one group than the other. The number of women reporting any adverse event was similar between anastrozole (1323 women, 91%) and tamoxifen (1379 women, 93%); the side-effect profiles of the two drugs differed, with more fractures, musculoskeletal events, hypercholesterolaemia, and strokes with anastrozole and more muscle spasm, gynaecological cancers and symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen. Conclusions No clear efficacy differences were seen between the two treatments. Anastrozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS, which may be be more appropriate for some women with contraindications for tamoxifen. Longer follow-up will be necessary to fully evaluate treatment differences